Place of ciclosporin A in modern therapy of rheumatoid arthritis


Cite item

Full Text

Abstract

The article dedicated to problem of treatment of rheumatoid arthritis (RA). At the present time, cyclosporine A (CyA) - immunosuppressant with selective effect on the T-lymphocytes especially without cytotoxic effects of immunosuppression - is effective medicine of pathogenetic therapy of RA in patients poor under the standard basic therapy or in cases ineffectiveness of treatment by methotrexate. CyA regimen in RA is well established and provides a treatment monitoring. In case of insufficient response to treatment, combined therapy including using a combination of CyA with genetically engineered biological reparations is feasible.

About the authors

E L Luchikhina

E L Luchihina

References

  1. Harris ED. Rheumatoid Arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
  2. Ревматология: Национальное руководство / Под ред. Е.Л. Насонова, В.А. Насоновой. М., 2008. 720 с.
  3. Насонов Е.Л. Ревматоидный артрит как общемедицинская проблема // Терапевтический архив. 2004. № 5. С. 5-7.
  4. Сигидин Я.А., Лукина Г.В. Ревматоидный артрит. М., 2001. 328 с.
  5. Nell V, Machold K, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
  6. Каратеев Д.Е. Фармакотерапия раннего ревматоидного артрита // Фарматека. 2006. № 6. С. 92-97.
  7. Каратеев Д.Е. Современная медикаментозная терапия ревматоидного артрита // Лечащий врач. 2007. № 2. С. 40-46.
  8. Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21-й век // Клиническая медицина. 2005. № 6. С. 8-12.
  9. Насонов ЕЛ. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов // Терапевтический архив. 2007. № 5. С. 5-8.
  10. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. и др. Современные стандарты фармакотерапии ревматоидного артрита // Клиническая фармакология и терапия. 2005. № 1. С. 72-75.
  11. Сигидин Я.А., Усова С.Б. Циклоспорин в терапии ревматоидного артрита // Клиническая фармакология и терапия. 1994. № 4. С. 26-28.
  12. Сигидин Я.А. Селективная иммунодепрессивная терапия ревматоидного артрита: препарат циклоспорин А // РМЖ. 1997. Т. 5. № 15.
  13. Langford CA, Klippel JH, Balow JE, et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease Part I: Rheumatologic and renal diseases. Ann Intern Med 1998;128:1021-28.
  14. Forre O, Bjerkhoel F, Salvesen CF, et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987;30:88-92.
  15. Tugwell P, Bombardier C, Gent M, et al. Low dose cyclosporine in rheumatoid arthritis: a pilot study. J Rheumatol 1987;14:1108-14.
  16. Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study. Ann Intern Med 1988;109:863-69.
  17. Ahern MJ, Harrison W, Hollingsworth P, et al. A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust N Z J Med 1991;21:844-49.
  18. Krüger K, Schattenkirchner M. Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis - results of a double-blind multicentre study. Clin Rheumatol 1994;13:8-55.
  19. Dijkmans BA, van Rijthoven AW, Goei The HS, et al. Cyclosporine in rheumatoid arthritis. Semin Arthritis Rheum 1992;22:30-36.
  20. Tugwell P. Cyclosporine in rheumatoid arthritis: documented efficacy and safety. Semin Arthritis Rheum 1992;21(6 Suppl. 3):30-38.
  21. Førre O. Cyclosporine in rheumatoid arthritis: an overview. Clin Rheumatol 1995;14(Suppl. 2):33-36.
  22. Yocum DE, Allard S, Cohen SB, et al. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: сomparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group. Rheumatology (Oxford). 2000;39:156-64.
  23. An International Consensus Report: The use of Ciclosporin A in rheumatoid arthritis. Brit J Rheumatol 1993;1:1-3.
  24. Tugwell P, Pincus T, Yocum DE, et al Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-34.
  25. Yocum DE. Combination therapy with cyclosporin in rheumatoid arthritis. Br J Rheumatol 1996;35(Suppl. 2):19-23.
  26. Stein CM, Pincus T. Combination treatment of rheumatoid arthritis with cyclosporine and methotrexate. Clin Exp Rheumatol 1999;17(6 Suppl. 18):S47-52.
  27. McKenna RM, Szturm K, Jefffery JR, et al. Inhibition of cytokine production by cyclosporin A and G. Transplantation 1989;47:343.
  28. Segal R, Mozes E, Yaron M, et al. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989;32:370-77.
  29. Sigal NH, Dumont FJ. Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992;10:519-60.
  30. Kremer JM. Methotrexate (MTX) induces significant changes in IL-1, IL-2, IL-6 and IL-8 but not lymphocyte markers in patients (PTS) with rheumatoid arthritis (RA). Arthritis Rheum 1993;36(Suppl.):S7.
  31. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.
  32. Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998;37:874-82.
  33. Chaudhuri K, Torley H, Madhok R. Disease-modifying anti-rheumatic drugs. Cyclosporin. Br J Rheumatol 1997;36:1016-21.
  34. Landewe RB, Goei The HS, van Rijthoven AW, et al. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637-43.
  35. van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. Rheumatol 1998;25:1493-98.
  36. Miranda JM, Alvarez-Nemegyei J, Saavedra MA, et al. A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 2004;35:36-42.
  37. Gerards AH, Landewe RB, Prins AP, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomized placebo controlled trial. Ann Rheum Dis 2003;62:291-96.
  38. Ferraccioli G, Gremese E, Tomiento P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford). 2002;41:892-98.
  39. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006;54:1401-09.
  40. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008;67:815-22.
  41. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-49.
  42. Bejarano V, Conaghan PG, Proudman SM, et al. Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. Ann Rheum Dis 2009;68:761-63.
  43. Temekonidis TI, Georgiadis AN, Alamanos Y, et al. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002;61:822-25.
  44. Voulgari PV, Alamanos Y, Drosos AA. Persistent clinical response of infliximab therapy in patients with refractory rheumatoid arthritis, over a 3-year period. Curr Clin Pharmacol 2006;1:103-08.
  45. Sidiropoulos PI, Siakka P, Raptopoulou A, et al. An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab. Ann Rheum Dis 2006;65:538-41.
  46. Giannitti C, Benucci M, Caporali R, et al. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol. 2009;22:543-46.
  47. Panayi GS, Tugwell P. The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol 1997;36:808-11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies